Bioprinting of Living Cells Report from IV Regenerative Medicine Workshop

Following the IV Regenerative Medicine Workshop on Bioprinting of Living Cells, organised by AMIRES, we are pleased to The bioprinting of living cells report from the IV Regenerative Medicine Workshop provides a comprehensive overview of the latest advancements, challenges, and opportunities shaping this rapidly evolving field.

Organised by AMIRES and held in Prague on 3 February 2026, the workshop brought together leading experts from research, clinical practice, industry, regulatory bodies, and patient organisations. The event created a multidisciplinary platform to explore how innovative bioprinting solutions can successfully transition from laboratory research to clinical trials and real-world

healthcare applications.

Key insights from the bioprinting of living cells report

The report captures the most relevant discussions and outcomes of the workshop, reflecting both the scientific progress and the systemic challenges that still need to be addressed.

Among the main highlights:

• Advances in EU-funded research focused on bioprinting of living cells
• Breakthrough technologies enabling more scalable and reproducible bioprinting processes
• Key considerations related to IP strategies, regulatory frameworks, and health technology assessment (HTA)
• Pathways supporting clinical translation and market uptake
• The importance of cross-European collaboration to accelerate innovation

The report also highlights the role of multidisciplinary collaboration, bringing together researchers, clinicians, industry stakeholders, and policy experts. Special attention was given to early-stage research showcased during the poster session, emphasising the importance of nurturing emerging talent in the field.

Supporting the path towards clinical application

Overall, the bioprinting of living cells report underlines the increasing maturity of biofabrication technologies and their strong potential to deliver tangible clinical impact. At the same time, it clearly outlines the steps that still need to be taken to ensure successful translation into safe, effective, and scalable healthcare solutions.

Powered by NEOLIVER.